Skip to main content

Table 2 Quality of life baseline scores as measured by the EORTC QLQ-C30 for each study arms

From: Quality of life in patients with advanced gastric cancer: a randomized trial comparing docetaxel, cisplatin, 5-FU (TCF) with epirubicin, cisplatin, 5-FU (ECF)

 

ECF group

TCF group

P

 

Mean (SD)

Mean (SD)

 

Functioning scores*

   

Physical functioning

65.3 (13.4)

66.1 (11.1)

0.79

Role functioning

68.5 (15.5)

68.0 (18.4)

0.89

Emotional functioning

64.0 (12.1)

56.6 (14.7)

0.02

Cognitive functioning

85.7 (10.8)

84.2 (14.3)

0.61

Social functioning

68.1 (13.6)

68.5 (13.1)

0.89

Global quality of life

55.2 (17.4)

45.1 (14.4)

0.01

Symptom scores**

   

Fatigue

43.5 (14.8)

49.6 (17.3)

0.11

Nausea and vomiting

22.8 (19.8)

33.8 (23.7)

0.04

Pain

40.0 (16.7)

47.1 (21.2)

0.12

Dyspnoea

7.62 (16.3)

12.0 (21.3)

0.33

Sleep difficulties

31.4 (25.5)

40.7 (21.2)

0.09

Appetite loss

39.0 (22.1)

46.3 (24.3)

0.19

Constipation

14.3 (21.8)

14.8 (26.9)

0.93

Diarrhoea

3.81 (10.7)

9.25 (18.8)

0.14

Financial difficulties

52.4 (20.2)

44.4 (21.1)

0.11

  1. * Higher scores show better functioning and global quality of life.
  2. ** Higher scores indicate greater symptoms.